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Abstract
Introduction: For early detection of breast cancer, the development of robust blood-based biomarkers that
accurately reflect the host tumor is mandatory. We investigated DNA methylation in circulating free DNA (cfDNA)
from blood of breast cancer patients and matched controls to establish a biomarker panel potentially useful for
early detection of breast cancer.
Methods: We examined promoter methylation of seven putative tumor-suppressor genes (SFRP1, SFRP2, SFRP5,
ITIH5, WIF1, DKK3, and RASSF1A) in cfDNA extracted from serum. Clinical performance was first determined in a test
set (n = 261 sera). In an independent validation set (n = 343 sera), we validated the most promising genes for
further use in early breast cancer detection. Sera from 59 benign breast disease and 58 colon cancer patients were
included for additional specificity testing.
Results: Based on the test set, we determined ITIH5 and DKK3 promoter methylation as candidate biomarkers with
the best sensitivity and specificity. In both the test and validation set combined, ITIH5 and DKK3 methylation
achieved 41% sensitivity with a specificity of 93% and 100% in healthy and benign disease controls, respectively.
Combination of these genes with RASSF1A methylation increased the sensitivity to 67% with a specificity of 69%
and 82% in healthy controls and benign disease controls, respectively.
Conclusions: Tumor-specific methylation of the three-gene panel (ITIH5, DKK3, and RASSF1A) might be a valuable
biomarker for the early detection of breast cancer.
Introduction
Breast cancer remains the most frequently diagnosed
cancer and the leading cause of cancer deaths in Eur-
opean women [1]. According to the World Health Orga-
nization (WHO), more than 449,000 women in Europe
will be diagnosed yearly with breast cancer, comprising
approximately 28% of all cancers in female patients.
Localized, early-stage breast cancer has a favorable prog-
nosis, with a 5-year survival rate of up to 98%. However,
the 5-year survival rate declines to 20% when the tumor
has metastasized [2]. Although clinical examination and
ultrasound provide a preliminary screening method, the
two most sensitive and specific detection methods to
date are mammography and magnetic resonance ima-
ging (MRI). Mammography has become the standard of
care in breast cancer screening. Mammograms are use-
ful in that they are reliable and sensitive enough to
detect ductal carcinoma in situ (DCIS). Nevertheless,
the limitations of mammography are well recognized
[3,4], such as the personal discomfort, the poor accuracy
in women with dense breast tissue, and a relatively high
rate of false positives. Clinically occult early-stage breast
cancer is often similar in appearance to a benign breast
lesion, resulting in unnecessary subsequent biopsies [3].
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In addition, more than 10% of breast tumors are missed by
mammography, leading to a sensitivity of 70% to 91% [5].
In contrast, MRI requires no breast compression and
offers excellent imaging around dense breast tissue. Unfor-
tunately, the high sensitivity (85% to 100%) of MRI is com-
promised by a high rate of false positives (37% to 100%),
which call for unnecessary follow-up examinations and
invasive biopsies [6]. Regarding these limitations of mam-
mography and MRI in population-based screening,
minimally invasive screening tests are desirable that could
complement mammography or MRI, or even stand alone
as a primary screening tool. Confidence is growing that
the next generation of screening tests will be based on
molecular biomarkers present in bodily fluids.
Determination of promoter methylation of tumor-sup-
pressor genes in the DNA of easily accessible bodily fluids,
like serum or plasma, is a rapidly growing research field in
cancer detection. The principle of DNA methylation mar-
kers for early breast cancer detection is based on evidence
that growing tumors release significant amounts of circu-
lating free DNA (cfDNA) into the bloodstream through
cellular necrosis, apoptosis, or spontaneous release of
DNA into the circulation from primary and metastatic
tumors [7,8]. The diagnostic potential of RASSF1A and
APC promoter methylation in cfDNA from breast cancer
patients has been investigated in several studies [9-12]. In
particular, RASSF1A methylation of cfDNA predicted the
presence of breast cancer with a sensitivity ranging from
15% to 75%, whereas with APC, methylation sensitivities
from 2% to 47% were achieved. For either, gene specificity
in healthy controls was claimed to be high (90% to 100%).
Although several potential DNA methylation biomarkers
have been reported, none of these has reached clinical
practice. A major limitation to further development for
clinical use might have been that these studies analyzed
small numbers of breast cancers and matched control spe-
cimens, and validations with larger patient cohorts were
not pursued [13-15]. Furthermore, investigations of the
methylation patterns in cfDNA from non-breast cancers
or different benign breast diseases to identify potential
specificity issues is lacking in most of these studies. Colon
cancer in women is by 60% less frequent than breast can-
cer [1] (for example, APC methylation is also detected in
cfDNA from colon cancer patients with considerable sen-
sitivity) [16]. Therefore, supposed specific biomarkers are
reduced in their overall specificity when analyzing addi-
tional serum samples from non-breast tumor patients. In
addition, fibroadenoma tumors, the most common benign
tumors in women, typically found during the middle and
later reproductive years, are a potential source for hyper-
methylated cfDNA [17], indicating that high specificity in
benign disease controls is mandatory to establish a suitable
biomarker panel for early breast cancer detection.
In the present study, seven potential breast cancer mar-
ker candidates (SFRP1, SFRP2, SFRP5, WIF1, DKK3,
ITIH5, and RASSF1A) were studied with regard to early
breast cancer detection in serum. These genes have pre-
viously shown cancer-specific methylation in breast tissue
[18-22]. So far, no studies have considered the promoter
methylation of these genes in a large set of breast cancer
serum samples, as well as different specificity controls. We
examined promoter methylation of these candidate genes
in two independent sets with a total of 604 serum samples
and 112 matched breast cancer tissues. In a test set (n =
261 sera; n = 112 tissues), we determined the best candi-
date markers with the highest specificity in age-matched
healthy and benign disease controls. An independent vali-
dation set (n = 343 sera) was then used to validate the top
genes obtained from the test study as reliable detection
markers.
Materials and methods
Patients
In total, 604 serum samples were assessed in this case-
control study. It included samples from patients with all
stages of breast cancer (n = 250 sera), cancer-free indivi-
duals (n = 237 sera), patients with benign breast disease
(n = 59 sera), and patients with colon cancer (n = 58 sera).
Importantly, 90% of the patients in both the test and the
validation set had small tumors (pT1 or pT2). Further-
more, asymptomatic women who, based on their family
history and/or mutational analysis, were suspected or pro-
ven to carry mutations in breast cancer susceptibility
genes (BRCA1 and BRCA2) or had a previous breast
tumor were not included in our group of healthy controls.
An overview of the analyzed serum sets is summarized in
Figure 1. A subset of 261 serum and 112 paired breast
cancer tissue samples was used as test set, and was
obtained from the tumor bank of Euregional comprehen-
sive Cancer Center Aachen (ECCA), now part of the
RWTH centralized biomaterial bank (RWTH cBMB). All
patients gave informed consent for retention and analysis
of their serum for research purposes (local ethical review
board of the medical faculty of the RWTH Aachen, ref no.
EK-206/09). The validation set consisted of 343 samples,
including clinicopathologically matched samples to the
test set. Samples of the validation set were obtained from
the University Hospital of Erlangen and from Patients’
Tumor Bank of Hope (PATH foundation, a research
resource for breast cancer biosamples) [23]. Additional
controls were collected from individuals with colon can-
cer, because colon cancer is the second common cancer
type in women. In addition, various sera from benign
breast disease patients, including fibroadenoma (n = 17),
desmoid tumors (n = 1), benign phyllodes tumors (n = 1),
mastopathy (n = 33), papilloma (n = 5), duct ectasia
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(n = 1), and harmatoma (n = 1) were analyzed for addi-
tional specificity testing. Additional control samples were
obtained from the RWTH cBMB. An overview of the clin-
ical characteristics of the breast cancer patients in the test
and validation set is summarized in Table 1. All subjects
participating were HIV, HBV, and HCV negative and had
no previous history of cancer. Blood from all patients was
drawn immediately or up to 2 days after diagnosis and
before starting any cancer-specific treatment. All patient
samples were collected between the years 2005 and 2012.
Tumor material was snap-frozen in liquid nitrogen
directly after surgery. Hematoxylin and eosin-stained
sections were prepared for assessment of the percentage
of tumor cells, but only samples with > 70% tumor cells
were selected. Blood samples (10 ml) from all study par-
ticipants were obtained by venipuncture. Samples were
immediately centrifuged at 2,000 g for 10 minutes at
room temperature, and 1-ml serum aliquots were stored
at -80°C until use.
Nucleic acid extraction
Genomic DNA from breast tumors was isolated by using
the QIAamp DNA Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturers’ recommendations.
CfDNA was extracted from 1 ml serum by using the
QIAamp Circulating Nucleic Acid Kit (Qiagen) according
to the manufacturer’s recommendations, eluted in 35 μl of
TE buffer, and quantified spectrophotometrically. In the
test set, the median quantity of cfDNA in breast cancer
serum was 903 ng DNA/ml serum (range, 304.5 to
8,291.5) and 889 ng DNA/ml serum (range, 297.5 to
1,893.5) in healthy controls. In the validation set, the med-
ian quantity of 791 ng DNA/ml serum (range, 164.5 to
1,680) cfDNA was obtained from breast cancer sera, and
833 ng DNA/ml (range, 332.5 to 3,010) from healthy con-
trols. DNA samples were stored at -80°C until use.
DNA bisulfite modification
The extracted tissue DNA and serum cfDNA was bisulfite-
converted by using the EZ DNA methylation kit (Zymo
Research, Orange, CA, USA) as previously described [18].
Methylation-specific polymerase chain reaction (MSP)
The methylation status of the different genes was deter-
mined qualitatively by methylation- specific polymerase
chain reaction (MSP) [24] and quantitatively by Methy-
Light technology [25]. For MSP, bisulfite-converted DNA
was amplified by using primer sets specific for unmethy-
lated and methylated promoter sequences in each candi-
date gene. PCRs were run in a volume of 25 μl, containing
20 ng bisulfite-modified DNA, 2.5 μl 10 × MSP PCR buffer
[26], 1.25 μl dNTPs (25 mM), 0.5 μl sense primer (10 μM),
0.5 μl antisense primer (10 μM), 1.25 units GoTaq Flexi
DNA polymerase (Promega, Madison, WI, USA) (0.25 μl
Taq + 4.75 μl H2O), and 14.25 μl H2O. The PCR profile
was 95°C for 5 minutes, 38 to 40 cycles at 95°C for 30
seconds, primer annealing at 59°C to 63°C for 30 seconds,
72°C for 30 seconds, and a final extension step at 72°C for
Figure 1 Overview of the analyzed serum samples in two independent sets and paired breast cancer tumor tissues. BBD, benign breast
disease; BC, breast cancer; CC, colon cancer;N, healthy normal.
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10 minutes. MSP primer sequences and annealing tem-
peratures are listed in Additional file 1. PCR amplificates
were electrophoresed on 3% agarose gels and evaluated
under ultraviolet light. Universal bisulfite-converted poly-
methylated and unmethylated DNA (Epi Tect Control
DNA Set, Qiagen) served as positive controls, and H2O
and genomic unmodified DNA were included as negative
controls in each run.
Quantitative methylation-specific polymerase chain
reaction (qMSP)
Bisulfite-modified DNA was used as template for fluores-
cence-based real-time PCR, as previously described [25].
Amplification reactions were carried out in triplicate in a
volume of 25 μl containing 20 ng bisulfite-modified serum
DNA, 12.5 μl IQ Supermix (Biorad, Munich, Germany),
0.75 μl sense primer (10 μM), 0.75 μl antisense primer
Table 1 Clinicopathologic parameters of patients with breast cancer in the test and validation sets
Categorization Test set (na = 112) % Validation set (na = 138) % P valueb
Age at diagnosis 0.327
Median 60 years (range, 36-87 years) 63 years (range, 33-86 years)
Menopausal status 0.791
Premenopausal 22 19.6 21 15.2
Postmenopausal 90 80.4 117 84.8
Tumor sizec 0.337
pT1 49 43.8 67 48.6
pT2 51 45.5 59 42.8
pT3 8 7.1 8 5.9
pT4 2 1.8 2 1.4
Unknown 2 1.8 2 1.4
Lymph node statusc 0.997
pN0 55 49.1 77 55.8
pN1 38 33.9 42 30.4
pN2 9 8.0 10 7.2
pN3 7 6.3 6 4.3
Unknown 3 2.7 3 2.2
Histologic type 0.617
Invasive ductal 89 79.5 115 83.3
Invasive lobular 15 13.4 17 12.3
Other 8 7.2 6 4.2
Tumor graded 0.175
G1 6 5.4 14 10.1
G2 62 55.4 76 55.1
G3 44 39.3 48 34.8
Estrogen-receptor statuse 0.293
Negative (IRS0-2) 22 19.7 27 19.5
Positive (IRS3-12) 84 75.0 109 78.9
Unknown 6 5.4 2 1.4
Progesterone-receptor statuse 0.112
Negative (IRS0-2) 30 26.8 39 28.2
Positive (IRS3-12) 76 68.0 96 69.3
Unknown 6 5.4 3 2.2
HER2 statusf 0.112
Negative (0; 1+; 2+) 90 80.4 114 82.6
Positive (3+) 14 12.5 20 14.9
Unknown 8 7.1 4 2.9
aOnly female patients with primary, unilateral, invasive breast cancer were included. bFisher Exact test at a two-sided significance level of 0.05. cAccording to
TNM classification by Sobin and Wittekind [41]. dAccording to Bloom and Richardson, as modified by Elston and Ellis [42]. eIRS, immunoreactive score according
to Remmele and Stegner [43]. fOverexpression for the HER2/neu gene was diagnosed analogous to the threshold of the DAKO-Score system based on IHC assay.
Percentages may not sum to 100% because of rounding.
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(10 μM), 0.5 μl probe (10 μM), and 10.5 μl H2O. Primers
and probes were designed specifically to amplify bisulfite-
converted DNA for the genes of interest (DKK3, ITIH5,
and RASSF1A) and the reference housekeeping gene
(GAPDH) to normalize for input DNA. Amplifications
were carried out by using the following profile: 95°C for
10 minutes, 40 to 50 cycles at 95°C for 15 seconds, and
primer annealing at 58°C to 66°C for 30 seconds. QMSP
primer sequences and annealing temperatures are listed in
Additional file 2.
Amplifications were performed in an iCycler iQ5 (Bio-
Rad). Each plate included positive controls for the methy-
lated sequence (in vitro methylated human leukocyte
DNA) and unmethylated sequence (human leukocyte
DNA from a healthy donor), as well as multiple water
blanks. Primer binding sites of the qMSP assays were
located in the same genomic promoter region as primers
used for MSP analyses.
Analytic performance of the blood-based qMSP assays
Leukocyte DNA from healthy individuals was methy-
lated with SssI (CpG) methyltransferase (New England
Biolabs, Beverly, MA, USA) to generate completely
methylated DNA. Serial dilutions (500 ng to 0.025 ng)
of this DNA were used to construct a calibration curve
for each plate. Control DNA for serial dilutions was
diluted before bisulfite conversion. All analyzed samples
were within the different assays range of sensitivity and
reproducibility, based on amplification of internal refer-
ence standard (cycle threshold (CT) value for GAPDH of
32 or less). The gene of interest was called methylated if
the CT of at least two of three PCR replicates for each
specimen had a value of less than 45 cycles. Genes of
interest were considered unmethylated if CT was not
measurable or was ≥ 45.0 and the GAPDH CT was ≥ 33
cycles. The amount of methylated DNA (percentage of
methylated reference, PMR) at a specific locus was cal-
culated by dividing the GENE/GAPDH ratio of a sample
by the GENE/GAPDH ratio of SssI-treated human leu-
kocyte DNA and multiplying by 100 [25]. Additionally,
analytic performance of the DKK3, ITIH5, and RASSF1A
assay was determined by using the in vitro methylated
human leukocyte DNA added in definite concentrations
(500 ng to 0.01 ng) to 1 ml disease-free human serum.
Next, the added methylated DNA was isolated and
bisulfite-treated as mentioned earlier. The detection
limit of DKK3 and RASSF1A methylation at the spe-
cimen level was 50 pg/ml, and of ITIH5 methylation,
100 pg/ml.
Statistical analysis
Statistical analyses were performed by using SPSS 17.0
(SPSS, Chicago, IL, USA) and GraphPad Prism 5.0
(GraphPad Software Inc., La Jolla, CA, USA). P values of
< 0.05 were considered significant. Two-sided Fisher
Exact tests were performed to compare clinicopathologic
factors between cohorts, and to correlate clinicopatholo-
gic parameters with the methylation values of the candi-
date genes in the test and validation sets. A Mann-
Whitney U test was used to detect significantly differen-
tial methylation levels between serum of age-matched
healthy women, benign breast diseases, sera from colon
cancers, and breast cancer. Mean methylation values of
the three-gene panel were visually compared by using
scatterplots of the log-transformed PMR values. Recei-
ver-operating-characteristics (ROC) curves were calcu-
lated to evaluate the diagnostic performance of different
marker combinations [27].
Results
Determination of the best-performing genes for a breast
cancer blood test with qualitative MSP
We initially assessed promoter methylation of SFRP1,
SFRP2, SFRP5, ITIH5, DKK3, and WIF1 in 112 paired
breast cancer tissue and serum samples by using qualita-
tive MSP. The majority of genes methylated in cfDNA
were also methylated in tissue DNA, whereas methylation
of tissue DNA was less frequently retrieved in cfDNA.
A significant positive correlation between promoter
methylation of DKK3 (P = 0.003) and ITIH5 (P = 0.007) in
paired tissue DNA and serum cfDNA was found (see
Additional file 3). SFRP2 was methylated in four cases, and
both SFRP1 and ITIH5 in two cases of cfDNA, with no
corresponding methylation in the paired-tissue DNA. In
general, methylation frequencies of ITIH5, WIF1, and
DKK3 in cfDNA were at least 36% compared with that of
tissue DNA, whereas SFRP1, SFRP2, and SFRP5 exhibited
just 9% to 24% of cfDNA methylation compared with the
methylation frequency in paired tissue DNA (Table 2).
Next, we investigated methylation of the six candidate
genes in 102 age-matched healthy controls and 47 addi-
tional disease controls. An overview of the methylation
frequencies in the studied serum samples of the test set is
given in Tables 2 and 3. Based on the methylation fre-
quencies, we defined for the most suitable genes for a clin-
ical assay the following criteria: methylated in ≤ 7% of
serum samples from healthy controls and benign disease
controls, ≤ 20% in colon cancer serum samples, and ≥ 20%
in serum samples from breast cancer patients. On the
basis of the defined criteria, SFRP5 methylation (8.25%)
was too infrequent in breast cancer sera, and thus
excluded from further specificity analyses. Similarly,
SFRP1 and SFRP2 showed high methylation rates in
healthy controls and benign disease samples (Table 3), and
thus were excluded.
Finally, WIF1 was excluded because this gene exhibited
an abundant methylation rate (25%) in serum samples
from benign breast diseases. Additional specificity testing
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in 27 colon cancer samples revealed moderate methyla-
tion frequencies in all candidate markers with the excep-
tion of DKK3 (Table 4). Two genes, ITIH5 and DKK3,
met our defined criteria, and were highly specifically
unmethylated in sera from healthy women and those
affected with benign disease, as well as sera from non-
breast tumors. In addition, only DKK3 and ITIH5 methy-
lation showed a significant concordance in tumor tissue
and paired serum specimens. The combination of DKK3
and ITIH5 (either gene methylated) substantially
improved sensitivity and specificity, which predicts breast
cancer with a sensitivity of 41% and a specificity of 93%,
100%, and 88% in age-matched healthy control samples,
benign breast disease, and colon cancer samples, respec-
tively. Considering all control samples, including sera
from patients with colon cancer, benign breast disease,
and healthy controls, yielded a specificity of 93% (139 of
149) with combined DKK3 and ITIH5 methylation.
Detection of breast cancer in an independent validation
set by using ITIH5, DKK3, and RASSF1A
To confirm the clinical performance of DKK3 and
ITIH5 methylation, we used serum samples from an
independent patient set. In the validation data analysis,
138 breast cancer samples, 135 samples from age-matched
healthy controls, and 70 additional disease controls were
analyzed. To increase the analytic sensitivity and to yield a
higher reproducibility [28,29] we analyzed the validation
set with qMSP. Primer binding sites of both the MSP and
the qMSP assays were located in the same genomic pro-
moter region but did not cover identical CpG dinucleo-
tides. Nevertheless, methylation frequencies of the
analyzed genes in the test and the validation sets were very
highly similar, independent of the technology applied. To
study the correlation between methylation obtained with
MSP and qMSP, serum samples of breast cancer patients
of the validation set, including negative and positive cases,
were reexamined with qualitative MSP. A significant posi-
tive correlation for both ITIH5 (P = 0.040) and DKK3 (P =
0.033) promoter methylation between both technologies
was found.
Methylation of DKK3 was present in serum from two
(1.5%) of 135 matched control subjects and 41 (29.7%)
of 138 breast cancer patients (P < 0.0001). In addition,
specificity in benign disease controls was high (all 39
(100%) samples were unmethylated). ITIH5 was methy-
lated in seven (5.2%) of 135 healthy controls, in one
(2.6%) of 39 benign controls, and 19 (13.8%) of 138
breast cancer samples. The combination of DKK3 and
ITIH5 methylation revealed a sensitivity of 39.9% (55 of
138) for the detection of breast cancer and a specificity
of 93.3% (126 of 135) and of 97.4% (38 of 39) in healthy
controls and benign disease controls (P < 0.0001),
respectively. In serum samples from patients with colon
cancer, DKK3 was detected in seven (22.6%) of 31,
whereas ITIH5 was present in nine (29%) of 31 cases
(Table 4).
To improve the sensitivity of the panel, we combined
DKK3 and ITIH5 with the potential biomarker
RASSF1A. RASSF1A methylation was significantly differ-
ent between serum of breast cancer patients (64 (47.1%)
of 136), and both healthy controls (35 (25.9%) of 135)
Table 2 Detection of aberrant gene promoter
methylation in paired samples (serum and tumor) in the
test set
Sensitivity in
breast cancer serum
Sensitivity in
breast cancer tissue
Gene Methylation
Positive
% Methylation
positive
%
ITIH5 27 of 112 24 81 of 112 72
DKK3 37 of 112 33 97 of 112 87
WIF1 39 of 112 35 108 of 112 96
SFRP1 12 of 112 11 89 of 111 79
SFRP2 21 of 112 19 90 of 112 80
SFRP5 9 of 112 8 104 of 110 93
DKK3/ITIH5a 46 of 112 41 105 of 112 94
aEither gene methylated.
Table 3 Sensitivity and specificity of serum-based detection of aberrantly methylated genes in the test set
Sensitivity in
breast cancer
Specificity in
healthy controls
Specificity in
benign breast diseases
Gene Methylation
positive
% Methylation
negative
% Methylation
negative
%
ITIH5 27 of 112 24 96 of 102 94 20 of 20 100
DKK3 37 of 112 33 101 of 102 99 20 of 20 100
WIF1 39 of 112 35 97 of 102 95 15 of 20 75
SFRP1 12 of 112 11 92 of 102 90 17 of 20 85
SFRP2 21 of 112 19 90 of 102 88 18 of 20 90
SFRP5 9 of 112 8 n.d. n.d.
DKK3/ITIH5a 46 of 112 41 95 of 102 93 20 of 20 100
aEither gene methylated. n.d., not done.
Kloten et al. Breast Cancer Research 2013, 15:R4
http://breast-cancer-research.com/content/15/1/R4
Page 6 of 11
(P = 0.0035) and benign disease controls (six (15.4%) of
39; P = 0.0013). The examination of 31 additional sam-
ples from patients with colon cancer indicated low spe-
cificity of RASSF1A methylation (42%) in cfDNA (Table
4). Figure 2 illustrates the distribution of mean PMR
values for the three-gene panel with ITIH5, DKK3, and
RASSF1A. A significant (P = 0.040) positive correlation
of the methylation status also was obtained with MSP
and qMSP in 12 samples (six negative and seven posi-
tive cases) of the validation set.
Next, we performed ROC curve analysis for multiple
marker combinations to determine both sensitivity and
specificity in breast cancer and control samples and to
calculate the optimal threshold value for the three-mar-
ker panel (Figure 3). According to this analysis, the
three-marker panel can discriminate between breast
cancer patients and women without breast cancer with a
sensitivity of 67% and a specificity of 69% (AUC, 0.697
(95% CI, 0.634 to 0.759)). Additionally, the three-marker
panel allowed distinguishing breast cancer patients from
women with a benign breast disease with high specificity
(82%; AUC, 0.765 (95% CI, 0.692 to 0.839)). The combi-
nation of healthy and benign controls revealed a specifi-
city of the three-marker panel of 72% (AUC, 0.712 (95%
CI, 0.653 to 0.770)). Combinations of different markers
were examined to maximize specificity and sensitivity.
The best combination remained with all three genes
(Table 5). Defining a cut-off value for the three-gene
panel of 0.085% for positive detection of methylation
(and thus disease), the panel distinguished between
breast cancer and both healthy and benign controls with
a sensitivity of 51.4% and a specificity of 80.5%.
Correlation of ITIH5, DKK3, and RASSF1A methylation with
clinicopathologic parameters
The methylation status of ITIH5, DKK3, and RASSF1A in
breast cancer tissue DNA and serum cfDNA in both the
test and validation sets was analyzed for association with
known clinicopathologic characteristics, including age at
diagnosis, tumor grade, tumor size, node status, hor-
mone-receptor status, and menopausal status. Detection
of ITIH5, DKK3, and RASSF1A methylation in the test
Figure 2 The biomarker panel including ITIH5, DKK3, and
RASSF1A enables significant discrimination of breast cancer
sera from various control conditions. Scatterplot illustrating the
mean PMR values of the three-gene panel in the independent
validation set. Combination of DKK3 and ITIH5 with RASSF1A
increased the sensitivity to 67% (92 of 138) with a specificity of 69%
(93 of 135) and 82% (32 of 39) in healthy and benign disease
controls, respectively. ***P < 0.0001.
Figure 3 ROC-curve analysis of the three-gene panel in control
samples including age-matched healthy and benign disease
controls. ROC curves were established for different biomarker
combinations to determine a cutoff value. A cutoff value of 0.085%
methylation was defined for positive detection of disease; the
specificity of the panel increased to 80.5% with a sensitivity of
51.4%. ROC analysis revealed an area under the curve (AUC) of 0.712
(95% CI, 0.653 to 0.770).
Table 4 Additional specificity testing of aberrantly
methylated genes in colon cancer in the test and
validation sets
Specificity in colon cancer
Test set Validation set
Gene Methylation
negative
% Methylation
negative
%
DKK3 27 of 27 100 24 of 31 77
ITIH5 24 of 27 89 22 of 31 71
WIF1 23 of 27 85 n.d.
SFRP1 16 of 22 73 n.d.
SFRP2 22 of 26 85 n.d.
SFRP5 n.d. n.d.
RASSF1A n.d. 13 of 31 42
DKK3/ITIH5a 24 of 27 88 16 of 31 52
Three-gene panela n.d. 6 of 31 19
aEither gene methylated. n.d., not done.
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and the validation sets was independent of patient age (P
> 0.05). However, in the test set, sensitivity of DKK3 and
ITIH5 methylation and sensitivity of the combined
methylation of DKK3/ITIH5 was more frequent in pre-
menopausal women. In the validation set, methylation
frequency of either DKK3, or methylation of the gene
combination DKK3/ITIH5 or methylation of the three-
gene panel was also increased in premenopausal women,
whereas the methylation frequency of RASSF1A was
more frequent in the postmenopausal subgroup. Area
under the curve (AUC) values were improved in preme-
nopausal women (see Additional file 4). Furthermore,
statistical investigations of the validation set revealed
a significant association of DKK3 cfDNA methylation
(P = 0.034) and cfDNA methylation of the DKK3 and
ITIH5 gene combination (P = 0.007) with smaller tumors
(pT1-2).
Discussion
In this study, we determined the performance of a blood-
based PCR assay for methylated cfDNA of seven potential
biomarkers in two independent serum sets with a total of
604 serum and 112 paired tumor tissue samples. Previous
studies showed the involvement of the candidate genes in
signal transduction of the WNT pathway (SFRP1, SFRP2,
SFRP5, DKK3, and WIF1) [19,20,22], invasion and metasta-
sis (ITIH5) (18), and regulation of apoptotic and cell-cycle
checkpoint pathways (RASSF1A) [30], suggesting a role in
breast carcinogenesis. The potential use of these genes,
except RASSF1A, as blood-based biomarkers for breast
cancer was not investigated previously. However, the high
methylation frequencies previously described for these
genes in breast tumor tissue suggested their potential feasi-
bility for early breast cancer detection in cfDNA. This is
the first study aiming to develop a blood-borne PCR assay
to detect breast cancer by using two independent series of
breast cancer serum samples, thus composing the largest
sample collection analyzed for serum-based cfDNA methy-
lation markers.
Methylation changes in carcinogenesis are often hetero-
geneous, and still no single gene has been found to be
methylated in every breast cancer specimen. Furthermore,
in most studies investigating methylation levels of only
single genes, the sensitivity was low [31]. Therefore, it is
considered advantageous to use a panel of genes for breast
cancer screening procedures. Recent studies have reported
a range of potential gene panels, including the most fre-
quently methylated genes in human breast cancer
[11,12,32-34]. In agreement with Van de Voorde et al.
[31], most of these potential biomarkers have been ana-
lyzed in relatively small patient cohorts, and further valida-
tion in larger-scaled patient and age-matched healthy
cohorts was not pursued. Furthermore, the frequent lack
of ROC analyses in most biomarker studies may result in
misinterpretation of the analyzed data [31]. Because of the
comparative analysis of 112 paired breast cancer tumor
tissues and serum samples, as well as the investigation of a
strong and realistic cohort of control samples in our study,
we were able to define a biomarker panel with the best
values for breast cancer specificity first in a test set. ITIH5
and DKK3 proved to be candidate genes showing a signifi-
cant correlation of the methylation pattern in paired
tumor tissue DNA and cfDNA. Concordance of the
methylation pattern found in tissue and serum specimens
indicates the potential utility of blood-based detection of
breast cancer. Furthermore, ITIH5 and DKK3 methylation
achieved 40% sensitivity with a high specificity in healthy
and benign disease controls. In an independent validation
set, DKK3 and ITIH5 were further validated in combina-
tion with the known biomarker RASSF1A to increase sen-
sitivity of the panel. Indeed, the combination of DKK3 and
ITIH5 with RASSF1A increased sensitivity from 40% to
67%, but specificity of RASSF1A in healthy controls was
quite low (100 (74%) of 135), resulting in a reduction of
Table 5 Sensitivity and specificity of breast cancer detection with different marker combinations
Sensitivity in
breast cancer
Specificity in healthy and benign breast disease controls P valueb AUC (95% CI) PPV NPV
Genea Methylation
positive
% Methylation
negative
% % %
RASSF1A
ITIH5
75 of 138 54 127 of 174 73 7.8 × e-6 0.647 (0.585-0.709) 61 67
RASSF1A
DKK3
82 of 138 59 131 of 174 75 1.6 × e-8 0.686 (0.626-0.747) 66 70
DKK3
ITIH5
55 of 138 40 164 of 174 94 1.6 × e-7 0.673 (0.611-0.735) 85 66
RASSF1A
DKK3
ITIH5
92 of 138 67 125 of 174 72 1.3 × e-10 0.712 (0.653-0.770) 65 73
aEither gene methylated. bFisher Exact test at a two-sided significance level of 0.05. AUC, area under the curve; CI, confidence interval; NPV, negative predictive
value; PPV, positive predictive value.
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specificity from 93% to 69% with the three-marker panel.
The combination of healthy and benign controls increased
specificity of the three-gene panel to 72%. Recent publica-
tions reported RASSF1A methylation frequencies of 32%
to 75% in cfDNA of breast cancer patients, in line with
our data from the validation set (sensitivity of 46%) [30].
In particular, Brooks et al. [12] investigated RASSF1A pro-
moter methylation in 50 breast cancer serum samples, 100
healthy, and 50 benign breast disease controls. Sensitivity
of RASSF1A was much lower (22%) than in our study,
whereas specificity in healthy controls was slightly higher.
However, specificity of RASSF1A was lower in our study
compared with that in other publications [10,34]. This
may be due to the examination of a larger set of age-
matched healthy control samples compared with these
studies. The potential biomarkers DKK3 and ITIH5 seem
to be more breast cancer specific (94% to 99%) but less
sensitive (14% to 33%) in both the test and the validation
sets. Nevertheless, DKK3 promoter methylation could
exhibit the feasibility to detect cfDNA methylation of
smaller tumors (pT1-2), which also remains valid in com-
bination with ITIH5. ROC analysis of cfDNA methylation
of pT1-2 tumors increased the sensitivity of the DKK3 and
ITIH5 gene combination in the validation set from 40% to
43% (AUC, 0.688 (95% CI, 0.624 to 0.752)), which might
indicate a potential benefit of DKK3 and ITIH5 for the
early detection of breast cancer. However, the validation
set comprised only 9% pT3-4 tumors, so further studies
are needed. Additionally, DKK3 and ITIH5 specificity in
colon cancer cfDNA is much higher in comparison to
RASSF1A, indicating the eligibility of DKK3 and ITIH5 as
potential breast cancer biomarkers.
Regarding mammography, with a sensitivity of 70% and
a specificity of > 85%, a reliable biomarker panel for the
early detection of breast cancer in cfDNA has to accom-
plish comparable values. However, sensitivity of mammo-
graphy declines drastically in patients with dense breast
tissue [35], and additionally, mammographic density is a
strong risk factor for breast cancer [36-38]. We hypothe-
size that DKK3 and ITIH5 may be valuable biomarkers for
the blood-based detection of breast cancer in patients with
dense breast tissue because of their high specificity in the
control specimens. Prospectively, DKK3 and ITIH5 methy-
lation analyses may be used in supplement to mammogra-
phy, the sensitivity of which is low in patients with dense
breast tissue. With ROC curve analysis, we examined
DKK3, ITIH5, and also RASSF1A methylation with regard
to sensitivity and specificity in pre- and postmenopausal
women. Interestingly, in the validation set, methylation of
either DKK3, or methylation of the DKK3/ITIH5 gene
combination or methylation of the three-gene panel
is more frequent in premenopausal women, whereas
RASSF1A methylation is increased in postmenopausal
women. In the validation set, ROC analysis of cfDNA
methylation of premenopausal women revealed a higher
sensitivity (52%) of the DKK3 and ITIH5 gene combina-
tion with a specificity of 100% (AUC, 0.762 (95% CI, 0.611
to 0.913)), whereas the DKK3 and ITIH5 gene combina-
tion exhibited a sensitivity of 36% with a specificity of 92%
(AUC, 0.647 (95% CI, 0.575 to 0.718)) in postmenopausal
women. These results might indicate a pronounced benefit
of DKK3 and ITIH5 for the early detection of breast can-
cer in premenopausal women. However, the premenopau-
sal subgroup in both test and validation sets comprised
only 15% to 20% of cases, so further studies are needed to
confirm this finding.
In summary, the three-marker panel with ITIH5,
DKK3, and RASSF1A exhibits significantly increased
levels of methylation in serum cfDNA from breast can-
cer patients compared with both age-matched healthy
women and women with a benign breast disease.
According to our data, RASSF1A promoter methylation
is not an ideal biomarker for early breast cancer detec-
tion because it shows a high frequency of methylation in
cfDNA derived from sera of healthy individuals. How-
ever, although DKK3 and ITIH5 are highly specific in
healthy and benign control samples, sensitivity of the
potential biomarkers is limited.
Our next goal is to discover and characterize more
potential biomarkers for early breast cancer detection
with a quality comparable to that of ITIH5 and DKK3
promoter methylation. In addition, other approaches
like investigations of copy-number variations (CNVs),
loss of heterozygosity (LOH), or point mutations in
cfDNA could be used to improve the sensitivity of the
two-gene combination. A study by Shaw et al. [39]
investigated CNVs and LOH in cfDNA of breast cancer
patients and matched controls and demonstrated differ-
ent potential gene targets that distinguish between
patients with primary breast cancer and healthy con-
trols. It is conceivable that DKK3 and ITIH5 sensitivity
could be improved through the additional investigation
of CNVs of genes like, for example, MAT1 or JAG2.
Another way to improve our approach could be the
additional analysis of gene mutations in cfDNA (such as
PIK3CA or TP53). Board et al. [40] investigated the
potential utility of cfDNA as a source for PIK3CA muta-
tion detection in patients with breast cancer. PIK3CA
mutations were detected in 13 (28%) of 46 plasma-
derived and 10 (21%) of 46 serum-derived cfDNA sam-
ples from metastatic breast cancer patients. Interestingly,
no PIK3CA mutations were detected in cfDNA from
localized breast cancers (n = 30). Altogether, this could
allow establishing a biomarker panel offering a sensitiv-
ity and specificity comparable to that of mammography
examination. Of importance, such a blood-borne screen-
ing test would be more convenient for the patient and
less expensive for the health-care system.
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Conclusions
Quantifying promoter methylation of putative tumor-
suppressor genes in circulating free DNA (cfDNA) of
bodily fluids, like serum, is a rapidly growing research
topic for early cancer detection. However, in the breast
cancer field, none of the reported biomarkers has
reached clinical application, mainly because of the small
numbers of breast cancer and matched control speci-
mens analyzed. In the current study, seven potential bio-
markers were evaluated in two independent serum sets
(n = 604). Promoter methylation of the DKK3/ITIH5
gene combination allowed significant discrimination of
breast cancer sera from various control conditions.
Moreover, these biomarkers showed the feasibility of
detecting cfDNA methylation even in smaller tumors
and in premenopausal women. A simple and noninva-
sive blood-borne screening test could complement
image-driven screening technologies like mammography
or magnetic resonance imaging (MRI) in early breast
cancer detection.
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